medigraphic.com

2019, Number 4

<< Back Next >>

Cir Cir 2019; 87 (4)

Expression of metalloproteinase-9 in patients with mild and severe forms of gastroesophageal reflux disease

Montiel-Jarquín ÄJ, Vázquez de Lara-Cisneros LG, López-Colombo A, Solís-Mendoza HA, Palmer-Márquez ML, Romero-Figueroa MS

Language: Spanish
References: 42
Page: 436-442
PDF size: 167.64 Kb.


ABSTRACT

Background: Gastroesophageal reflux disease develops when the stomach contents causes troublesome symptoms and complications. Mild forms are non-erosive and erosive esophagitis, and severe forms are Barrett’s esophagus and Esophageal adenocarcinoma. Matrix metalloproteinases are endopeptidases that can degrade components of the extracellular matrix, they play an important role in tumor invasion as well as in metastasis. Objective: To correlate the expression of metalloproteinase 9 (MMP-9) in esophageal biopsies from patients with mild and severe forms of Gastroesophageal reflux disease. Method: Cross-sectional study. The expression of MMP-9 was determined in biopsies of esophageal tissue of patients with mild and severe GRD. The included variables were age, sex, diagnosis, smoking and alcoholic habits, body mass index (BMI) and expression of MMP-9. Descriptive statistics was performed, Kappa for concordance in diagnosis as well as χ2. Results: There were 50 patients, 32 (64%) men and 18 (36%) women, mean age 52.13 ± 14.75 years of age. 12 (24%) with smoking and 7 (14%) with alcoholism. Average BMI was 26.71 ± 4.07 kg/m2 (15 to 33); 40 (80%) with obesity. The inter observer concordance for histopathological diagnosis was 1.0 and 0.84 for esophagitis degrees. 27 (54%) patients had esophagitis, 16 (32%) Barrett’s esophagus and 7 (14%) esophageal cancer. There was expression of MMP-9 in four patients with esophagitis, five with Barrett’s esophagus and five with esophageal cancer. Statistical significance was found between the expression of MMP- 9 and smoking (p = 0.011) and histopathological diagnosis (p = 0.052). Conclusions: The expression of MMP-9 is most common in severe forms compared to the mild forms of GRD.


REFERENCES

  1. Montiel-Jarquín AJ. Expresión de la metaloproteinasa 9 en pacientes con formas leves y graves de enfermedad por reflujo gastroesofágico. [Tesis de Maestría en Ciencias Médicas e Investigación, BUAP-IMSS]. Puebla, México; 2011.

  2. Uscanga L, Nogueira-de-Rojas JR, Gallardo E, Bernal-Reyes R, González M, Ballesteros-Amozurrutia A. Gastroesophageal reflux disease. Gastroenterology Mexican association consensus. Mexican group for the GERD study. Rev Gastroenterol Mex. 2002;67:216-23.

  3. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R: [The Montreal definition and classification of gastroesophageal reflux disease: a global, evidence-based consensus paper]. Z Gastroenterol. 2007;45:1125-40.

  4. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17-26.

  5. Locke GR, III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ, III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-56.

  6. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976;21:953-6.

  7. Thompson WG, Heaton KW. Heartburn and globus in apparently healthy people. Can Med Assoc J. 1982;126:46-8.

  8. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol Suppl. 1989;156:7-13.

  9. López-Colombo A, Morgan D, Bravo-González D, Montiel-Jarquín A, Méndez-Martínez S, Schmulson M. The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study. Gastroenterol Res Pract. 2012;2012 606174.

  10. Peralta-Pedrero ML, Lagunes-Espinosa AL, Cruz-Avelar A, Juárez-Cedillo T, Rodríguez-Moctezuma R, López-Carmona JM, et al. [Frequency of gastroesophageal reflux disease in elderly patients attending a family medicine clinic]. Rev Med Inst Mex Seguro Soc. 2007;45:447-52.

  11. Wong WM, Lai KC, Lam KF, Hui WM, Hu WH, Lam CL, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther. 2003;18:595-604.

  12. Hui TT, Fass SM, Giurgiu DI, Iida A, Takagi S, Phillips EH. Gastroesophageal disease and nausea: does fundoplication help or hurt? Arch Surg. 2000;135:545-9.

  13. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults — update 2004. Can J Gastroenterol. 2005;19:15-35. 12.

  14. Chen M, Xiong L, Chen H, Xu A, He L, Hu P. Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a population- based study in South China. Scand J Gastroenterol. 2005;40:759-67.

  15. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet. 1990;335:205-8.

  16. Lim SL, Goh WT, Lee JM, Ng TP, Ho KY. Changing prevalence of gastroesophageal reflux with changing time: longitudinal study in an Asian population. J Gastroenterol Hepatol. 2005;20:995-1001.

  17. Segal I. The gastro-oesophageal reflux disease complex in sub-Saharan Africa. Eur J Cancer Prev. 2001;10:209-12.

  18. Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96:2905-14.

  19. Flook N, Jones R, Vakil N. Approach to gastroesophageal reflux disease in primary care: putting the Montreal definition into practice. Can Fam Physician. 2008;54:701-5.

  20. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease — current concepts and dilemmas. Am J Gastroenterol. 2001;96:303-14.

  21. Fass R, Hell RW, Garewal HS, Martinez P, Pulliam G, Wendel C, et al. Correlation of oesophageal acid exposure with Barrett’s oesophagus length. Gut. 2001;48:310-3.

  22. Fass R, Ofman JJ. Gastroesophageal reflux disease — should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901-9.

  23. Fass R, Sampliner RE. Barrett’s oesophagus: optimal strategies for prevention and treatment. Drugs. 2003;63:555-64.

  24. Kerkhof M, van Dekken H, Steyerberg EW, Meijer GA, Mulder AH, de Bruïne A, et al. Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology. 2007;50:920-927.

  25. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 2002;97:1888-95.

  26. Pedrazzani C, Catalano F, Festini M, Zerman G, Tomezzoli A, Ruzzenente A, et al. Endoscopic ablation of Barrett’s esophagus using high power setting argon plasma coagulation: a prospective study. World J Gastroenterol. 2005;11:1872-5.

  27. Munitiz V, Martínez de Haro LF, Ortiz MA, Ruiz de AD, Molina J, Bermejo J, et al. Surgical treatment of high-grade dysplasia in Barrett’s esophagus. Cir Esp. 2007;82:214-8.

  28. Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg. 2003;76:S1367-9.

  29. Van CE, Vantrappen G. Epidemiology and clinical aspects of esophageal cancer. J Belge Radiol. 1991;74:365-8.

  30. Yamamoto H, Vinitketkumnuen A, Adachi Y, Taniguchi H, Hirata T, Miyamoto N, et al. Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma. Carcinogenesis. 2004;25:2353-60.

  31. Gu ZD, Chen KN, Li M, Gu J, Li JY. Clinical significance of matrix metalloproteinase- 9 expression in esophageal squamous cell carcinoma. World J Gastroenterol. 2005;11:871-4.

  32. Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa T, et al. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer. 1992;70:2747-53.

  33. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996;56:190-6.

  34. Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN, Jr., et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 2006;12:1707-14.

  35. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-503.

  36. Beranek M, Kolar P, Tschoplova S, Kankova K, Vasku A. Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Mol Vis. 2008;14:1114-21.

  37. Herszenyi L, Hritz I, Pregun I, Sipos F, Juhasz M, Molnar B, et al. Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol. 2007;13:676-82.

  38. Grimm M, Lazariotou M, Kircher S, Stuermer L, Reiber Ch, Höfelmayr A, et. al. MMP-1 is a (pre-) invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status. J Translational Med 2010;8:99.

  39. Kollarova H, Machova L, Horakova D, Janoutova G, Janout V. Epidemiology of esophageal cancer - an overview article. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151:17-20.

  40. Samantaray S, Sharma R, Chattopadhyaya TK, Dattta S, Gupta R. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2004;130:37-44.

  41. Mukherjee S, Roth MJ, Dawsey SM, Yan W, Rodríguez-Canales J, Erickson HS, et al. Increased matrix metalloproteinase activation in esophageal squamous cell carcinoma. J Translational Med 2010;8:91.

  42. Ohashi K, Nemoto T, Nakamura K, Nemori R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer. 2000;88:2201-9.




2020     |     www.medigraphic.com